Key Points
- EVP Paul Mahon sold 8,300 United Therapeutics shares at an average price of $517.05, for proceeds of approximately $4.29 million. The sale reduced his direct holdings by 15.52% to 45,172 shares.
- United Therapeutics beat quarterly EPS expectations, reporting $7.27 per share versus the $6.86 consensus, although revenue fell 1.9% year over year to $783.3 million and missed estimates.
- Analysts remain generally bullish: 11 analysts rate the stock Buy and two rate it Hold, producing a Moderate Buy consensus and a $646 average price target. Institutional investors own 94.08% of the company.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the company's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $517.05, for a total value of $4,291,515.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $23,356,182.60. This trade represents a 15.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
United Therapeutics Trading Up 2.7%
NASDAQ UTHR opened at $532.94 on Friday. The stock has a fifty day simple moving average of $539.78 and a 200-day simple moving average of $534.19. The stock has a market cap of $22.62 billion, a PE ratio of 19.07, a P/E/G ratio of 1.74 and a beta of 0.59. United Therapeutics Corporation has a twelve month low of $292.34 and a twelve month high of $609.35.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period in the previous year, the firm earned $6.41 EPS. United Therapeutics's revenue was down 1.9% on a year-over-year basis. Research analysts predict that United Therapeutics Corporation will post 26.65 EPS for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on UTHR. TD Cowen restated a "buy" rating on shares of United Therapeutics in a report on Thursday, May 21st. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a report on Thursday. JPMorgan Chase & Co. upped their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research note on Thursday, July 23rd. Wells Fargo & Company upgraded United Therapeutics from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, Raymond James Financial assumed coverage on United Therapeutics in a research report on Friday, April 10th. They set an "outperform" rating and a $700.00 price target for the company. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $646.00.
Read Our Latest Stock Analysis on UTHR
Institutional Trading of United Therapeutics
Several hedge funds have recently modified their holdings of the stock. Leuthold Group LLC raised its position in United Therapeutics by 41.4% in the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company's stock valued at $5,200,000 after purchasing an additional 3,126 shares in the last quarter. UBS Group AG grew its position in shares of United Therapeutics by 45.3% during the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company's stock worth $110,045,000 after buying an additional 70,445 shares in the last quarter. Nicholas Investment Partners LP increased its stake in shares of United Therapeutics by 478.5% during the fourth quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company's stock worth $2,218,000 after buying an additional 3,766 shares during the period. LBP AM SA purchased a new stake in shares of United Therapeutics during the fourth quarter worth approximately $9,745,000. Finally, M&T Bank Corp raised its holdings in United Therapeutics by 171.6% in the fourth quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company's stock valued at $1,531,000 after acquiring an additional 1,985 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.
United Therapeutics News Summary
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: Quarterly EPS exceeded expectations. United Therapeutics reported second-quarter earnings of $7.27 per share, above the approximately $6.82–$6.86 consensus and up from $6.41 a year earlier. Strong profitability, including a net margin above 40%, provides a supportive fundamental backdrop. United Therapeutics Q2 Earnings Surpass Estimates
- Positive Sentiment: Ralinepag remains a major potential catalyst. Management highlighted the submission of regulatory applications for ralinepag, while the Phase 3 program and other pipeline developments could diversify growth beyond the company’s established pulmonary hypertension products. Analysts view these milestones as helping offset near-term competitive pressure on Tyvaso. EPS Strength and Ralinepag’s Phase 3 Milestone
- Positive Sentiment: Analysts remain constructive. H.C. Wainwright reiterated a Buy rating with a $660 target, while RBC maintained Outperform despite lowering its target from $704 to $677. The revised RBC target still implies substantial upside based on the quoted market price. Buy Rating Reiterated on United Therapeutics
- Neutral Sentiment: Revenue missed expectations. Second-quarter revenue declined roughly 2% year over year to $783.3 million, below the $804.65 million analyst estimate. The shortfall reflects near-term pressure despite the EPS beat and pipeline progress. United Therapeutics Reports Second-Quarter Results
- Negative Sentiment: Executives disclosed sizable stock sales. CEO Martine Rothblatt sold 9,500 shares for approximately $4.9 million, and EVP Paul Mahon sold 8,300 shares for about $4.3 million. Although these transactions may be scheduled or personal, they represent reductions in insider ownership and can weigh on sentiment.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
